-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FLmhB1GqiLvLjiyqOieLcW+Gfj9nhAKasmM0vfTUzX493uUSMcqFYHfFxm39dKSh
 wg8MhyWrqsrH/yCkc0qecg==

<SEC-DOCUMENT>0000950123-10-057561.txt : 20100611
<SEC-HEADER>0000950123-10-057561.hdr.sgml : 20100611
<ACCEPTANCE-DATETIME>20100611153503
ACCESSION NUMBER:		0000950123-10-057561
CONFORMED SUBMISSION TYPE:	RW
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20100611
DATE AS OF CHANGE:		20100611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		RW
		SEC ACT:		
		SEC FILE NUMBER:	333-147997
		FILM NUMBER:		10892578

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>RW
<SEQUENCE>1
<FILENAME>c02366rw.htm
<DESCRIPTION>RW
<TEXT>
<HTML>
<HEAD>
<TITLE>RW</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
200 Connell Drive, Suite&nbsp;1500<BR>
Berkeley Heights, NJ 07922<BR>
(908)&nbsp;517-7330</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">June&nbsp;11, 2010
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B>Via EDGAR and by Federal Express</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">U.S. Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
100 F Street, N.E.<BR>
Mail Stop 4561<BR>
Washington, D.C. 20549<BR>
Attention of: Bryan Pitko, Esq.

</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Re:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Cyclacel Pharmaceuticals, Inc.<BR>
Post-effective Amendment No.&nbsp;1 to Form&nbsp;S-3 on Form&nbsp;S-1<BR>
Filed on May&nbsp;27, 2010<BR>
File Number 333-147997</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Ladies and Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">With reference to your letter dated June&nbsp;9, 2010, and pursuant to Rule&nbsp;477 under the
Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), Cyclacel Pharmaceuticals, Inc. (the
&#147;<B>Registrant</B>&#148;), hereby requests that the above captioned Post-effective Amendment No.&nbsp;1 to Form S-3
on Form S-1 filed on May&nbsp;27, 2010 (the &#147;<B>Filing</B>&#148;) be withdrawn as of the date hereof or as soon
thereafter as practicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Registrant is withdrawing the Filing at the request of the Securities and Exchange
Commission pursuant to its letter to the Company dated June&nbsp;9, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">No securities were sold pursuant to the Filing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company requests in accordance with Rule 457(p) promulgated under the Securities Act that
all fees paid to the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) in connection with the
filing of the Registration Statement be credited for use in connection with a Registration
Statement on Form S-1 being filed by the Company on the date hereof covering the securities that
were the subject of the Filing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">It is our understanding that this application for withdrawal of the Registration Statement
will be deemed granted as of the date that it is filed with the Commission unless, within fifteen
days after such date, the Company receives notice from the Commission that this application will
not be granted. If any further information is required in connection with this matter, please
contact Todd E. Mason at (212)&nbsp;935-3000.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
<BR>
<BR>
<B>CYCLACEL PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Paul McBaron
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Paul McBarron&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Operating Officer, Chief Financial Officer and
Executive Vice President, Finance</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
